{"symbol":"LLY","fiscalQuarter":"Q4-2017","reportDate":"2018-01-31","reportTime":"BMO","status":"reported","company":{"name":"Eli Lilly and Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/LLY/earnings/Q4-2017","postBrief":{"headline":"Eli Lilly Beats on EPS, Stock Down 5.39%","keyNumbers":[{"metric":"EPS","actual":"$1.14","expected":"N/A","surprise":"+3.72%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted ongoing investments in research and development.","They noted a strong pipeline of products expected to drive future growth."],"summary":"Overall, management expressed confidence in the company's future prospects despite the lack of revenue guidance. They emphasized their commitment to innovation and market expansion."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Eli Lilly's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 5.39%, likely due to the absence of revenue figures and guidance, which left investors uncertain about future performance. The management's cautious tone may also have contributed to the stock's decline.","metaDescription":"Eli Lilly (LLY) Q4 2017 earnings: EPS beat by 3.72%. Stock down 5.39%. Full breakdown."}}